培美曲塞联合奈达铂治疗晚期肺腺癌的临床观察  

Clinical Observation of Pemetrexed Combined Nedaplat in the Treatment of Patients with Advanced Lung Adenocarcinoma

作　　者：顾胤 魏荣富[1] 李双根[1] 胡骏[1] 

机构地区：[1]江苏省高淳县人民医院肿瘤科,211300

出　　处：《医学理论与实践》2013年第21期2809-2810,2822,共3页The Journal of Medical Theory and Practice

摘　　要：目的:评价培美曲塞联合奈达铂治疗晚期肺腺癌的疗效及不良反应。方法:入组32例经病理确诊的晚期肺腺癌患者,给予培美曲塞500mg/m2静滴,第1天;奈达铂80mg/m2静滴,第1天,3周为1个周期,2个周期后评价疗效及不良反应。结果:32例患者中完全缓解(CR)0例,部分缓解(PR)9例,稳定(SD)15例,进展(PD)8例。有效率RR(CR+PR)28.1%。中位生存期11.8个月,1年存活率46.9%。结论:培美曲塞联合奈达铂治疗晚期肺腺癌具有较好的疗效及安全性。Objective：To observe the therapeutic effect and toxicity of Pemetrexed combined Nedaplat in the treatment of patients with advanced lung adenocarcinoma. Methods： The 32 patients with pathologically confirmed lung adenocar- cinoma were treated with Pemetrexed 500mg/m^2 and Nedaplat 80mg/m^2 , dl, ivdrip, the schedule was repeated every 3 weeks and were evaluated effect after 2 cycles. Results： No patients had complete response（CR）, 9 patients had partial response（PR）, 15 patients had SD, 8 patients had PD, RR（CR＋PR）28. 1 % （9/32）. The median survival time was 11.8 months. The 1-year survival rate was 46. 9 %. Condusion：The pemetrexed combined nedaplat is effective and safe in the treatment of advanced lung adenocarcinoma patients.

关 键 词：培美曲塞 奈达铂 肺腺癌 化学治疗 

分 类 号：R734.2[医药卫生—肿瘤]